Survival of the Upper-Urothelial-Cancer Patients from the Balkan Nephropathy Endemic and Nonendemic Areas

1988 ◽  
Vol 15 (1-2) ◽  
pp. 59-61 ◽  
Author(s):  
S. Janković ◽  
J. Marinković ◽  
Z. Radovanović
Keyword(s):  
Cancer Patients ◽  
Urothelial Cancer ◽  
Balkan Nephropathy ◽  
Upper Urothelial Cancer

scholarly journals Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients

2018 ◽  
Vol 16 (1) ◽  
pp. 90-98.e1 ◽  
Author(s):  
Janice M. Loh ◽  
Adrienne L. Tran ◽  
Lingyun Ji ◽  
Susan Groshen ◽  
Siamak Daneshmand ◽  
...  
Keyword(s):  
Glomerular Filtration Rate ◽  
Glomerular Filtration ◽  
Cancer Patients ◽  
Filtration Rate ◽  
Urothelial Cancer ◽  
Renal Toxicity

scholarly journals 765P Predicting survival in urothelial cancer patients after immunotherapy using real-world data

2020 ◽  
Vol 31 ◽  
pp. S590
Author(s):  
T. Elumalai ◽  
C. Aversa ◽  
B. Buijtenhuijs ◽  
R. Conroy ◽  
W. Croxford ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Real World ◽  
Urothelial Cancer ◽  
Real World Data ◽  
World Data

scholarly journals Transcriptional Profiling of Advanced Urothelial Cancer Predicts Prognosis and Response to Immunotherapy

2020 ◽  
Vol 21 (5) ◽  
pp. 1850 ◽  
Author(s):  
Seung-Woo Baek ◽  
In-Hwan Jang ◽  
Seon-Kyu Kim ◽  
Jong-Kil Nam ◽  
Sun-Hee Leem ◽  
...  
Keyword(s):  
Cell Cycle ◽  
Survival Analysis ◽  
Cancer Patients ◽  
Immune Checkpoint ◽  
Urothelial Cancer ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Prognostic Impact ◽  
T Effector Cells ◽  
Advanced Urothelial Cancer

Recent investigations reported that some subtypes from the Lund or The Cancer Genome Atlas (TCGA) classifications were most responsive to PD-L1 inhibitor treatment. However, the association between previously reported subtypes and immune checkpoint inhibitor (ICI) therapy responsiveness has been insufficiently explored. Despite these contributions, the ability to predict the clinical applicability of immune checkpoint inhibitor therapy in patients remains a major challenge. Here, we aimed to re-classify distinct subtypes focusing on ICI responsiveness using gene expression profiling in the IMvigor 210 cohort (n = 298). Based on the hierarchical clustering analysis, we divided advanced urothelial cancer patients into three subgroups. To confirm a prognostic impact, we performed survival analysis and estimated the prognostic value in the IMvigor 210 and TCGA cohort. The activation of CD8+ T effector cells was common for patients of classes 2 and 3 in the TCGA and IMvigor 210 cohort. Survival analysis showed that patients of class 3 in the TCGA cohort had a poor prognosis, while patients of class 3 showed considerably prolonged survival in the IMvigor 210 cohort. One of the distinct characteristics of patients in class 3 is the inactivation of the TGFβ and YAP/TAZ pathways and activation of the cell cycle and DNA replication and DNA damage (DDR). Based on our identified transcriptional patterns and the clinical outcomes of advanced urothelial cancer patients, we constructed a schematic summary. When comparing clinical and transcriptome data, patients with downregulation of the TGFβ and YAP/TAZ pathways and upregulation of the cell cycle and DDR may be more responsive to ICI therapy.

Sign in / Sign up

Export Citation Format

Share Document